Serum CA 19-9 as a good prognostic biomarker in patients with bladder cancer.

BACKGROUND Bladder cancer (BC) is the second leading malignant tumors of the genitourinary system. CA 19-9 has served as a diagnostic and prognostic marker for pancreatic carcinoma for years. In recent year, although a few studies have evaluated the roles of CA 19-9 in BC, the results are conflicting and the number of the patients studied is very small. AIM To investigate the potential of serum CA 19-9 to serve as a diagnostic and prognostic marker of BC in a larger number of patients. METHODS A total of 272 (144 BC patients and 128 healthy subjects) were enrolled. Patients were followed-up routinely at 3-month intervals for 5 years. Serum CA 19-9 level was detected by ELISA. RESULTS CA 19-9 level was much higher than that in healthy subjects (43.69 ± 6.92 U/ml vs. 12.31 ± 4.39 U/ml, p < 0.001). However, when the value of 37 U/ml of serum CA 19-9 was used as the cut-off value for BC the sensitivity of CA 19-9 for BC was dropped to 38.8%. CA 19-9 was much higher in muscle invasive tumor subgroup than that in superficial tumor subgroup (38.09 ± 7.14 U/ml vs. 20.71 ± 4.15 U/ml, p < 0.027). CA 19-9 level was comparable in both subgroups (29.78 ± 5.07 U/ml vs. 26.13 ± 5.97 U/ml, p = 0.565). BC patients with more than 5 years survival time had lower serum CA 19-9 level than the rest (15.86 U/ml vs 46.68 U/ml, p < 0.001). Survival rate (>5 years) of patients with lower CA 19-9 levels (<29 U/ml) was significantly increased in comparison to those with elevated serum CA 19-9 levels (>29 U/ml) (p < 0.001). CONCLUSIONS serum CA 19-9 is not a good diagnostic maker, but a very powerful prognostic marker for BC. Such a study might be helpful for urologists to manage patients with BC.

[1]  M. Knowles,et al.  A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges , 2012, Advances in urology.

[2]  K. Muro,et al.  CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy , 2014, Cancer Chemotherapy and Pharmacology.

[3]  S. Myung,et al.  A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve , 1999, American Journal of Gastroenterology.

[4]  T. Ørntoft,et al.  Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. , 1999, Clinical chemistry.

[5]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[6]  N. D. Merrett,et al.  The prognostic and predictive value of serum CA19.9 in pancreatic cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Daneshmand,et al.  Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: prognostic value in invasive urothelial carcinoma of the bladder. , 2014, Urologic oncology.

[8]  Michael B. Cohen,et al.  FISHing and beyond in urinary cytology , 2004, Diagnostic cytopathology.

[9]  S. Marionneau,et al.  ABH and Lewis histo‐blood group antigens in cancer , 2001, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[10]  D. Margel,et al.  A novel algorithm to improve pathologic stage prediction of clinically organ‐confined muscle‐invasive bladder cancer , 2009, Cancer.

[11]  D. Jin,et al.  Combined Serum CA19-9 and miR-27a-3p in Peripheral Blood Mononuclear Cells to Diagnose Pancreatic Cancer , 2013, Cancer Prevention Research.

[12]  C. Ohyama.  Glycosylation in bladder cancer , 2008, International Journal of Clinical Oncology.

[13]  C. Marsit,et al.  Body mass and smoking are modifiable risk factors for recurrent bladder cancer , 2014, Cancer.

[14]  S. Mondal,et al.  Urinary level of CA19-9 as a tumor marker in urothelial carcinoma of the bladder. , 2011, Urology journal.

[15]  S. Serrano,et al.  LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk , 2014, British Journal of Cancer.

[16]  B. Qasim,et al.  CD10 and CA19.9 immunohistochemical expression in transitional cell carcinoma of the urinary bladder , 2013, Urology annals.

[17]  M. Soloway,et al.  Expectant management of small, recurrent, noninvasive papillary bladder tumors. , 2003, The Journal of urology.

[18]  G. Hermann,et al.  Outpatient diagnostic of bladder tumours in flexible cystoscopes: Evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies , 2012, Scandinavian journal of urology and nephrology.

[19]  D. Margel,et al.  Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer. , 2007, The Journal of urology.

[20]  Yuri Watanabe,et al.  Anaplastic transformation from papillary thyroid carcinoma with increased serum CA19‐9 , 2005, Pediatric blood & cancer.

[21]  Ajit Kumar,et al.  Eukaryotic Gene Expression , 1984, GWUMC Department of Biochemistry Annual Spring Symposia.

[22]  S. Felknor,et al.  An Updated Review of the Literature: Risk Factors for Bladder Cancer with Focus on Occupational Exposures , 2006, Southern medical journal.

[23]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[24]  B. Eshrati,et al.  Prominent bladder cancer risk factors in Iran. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[25]  D. M. Lloyd,et al.  Elevation of Carbohydrate Antigen 19.9 in Benign Hepatobiliary Conditions and Its Correlation with Serum Bilirubin Concentration , 2008, Digestive Diseases and Sciences.

[26]  N. Petrelli,et al.  Serum levels of cancer‐associated antigen ca‐195 in gastrointestinal cancers and its comparison with ca19‐9 , 1989, Journal of clinical laboratory analysis.